Beneficial Ownership Report · SCHEDULE 13G/A
Bio-Techne Corp
TECHNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- BIO-TECHNE CORP
- Company CIK
- 0000842023
- Street
- 614 McKinley Place N.E.
- City
- Minneapolis
- State / country code
- MN
- Postal code
- 55413
Statement details
- Amendment number
- 2
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- FMR LLC
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 1,088,114.27
- Percent of class
- 0.7
- Sole voting power
- 1,005,122.07
- Shared voting power
- 0.00
- Sole dispositive power
- 1,088,114.27
- Shared dispositive power
- 0.00
Reporting person 2
- Name
- Abigail P. Johnson
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 1,088,114.27
- Percent of class
- 0.7
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 1,088,114.27
- Shared dispositive power
- 0.00
Item 1
Issuer
BIO-TECHNE CORP
Principal executive office address
614 McKinley Place N.E.,Minneapolis,MN,USA,55413
Item 2
Citizenship
Not applicable
Filing person
FMR LLC
Principal business or residence address
245 Summer Street, Boston, Massachusetts 02210
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
0.7
Amount beneficially owned
1088114.27
Sole voting power
Please see the responses to Items 5 and 6 on the cover page.
Shared voting power
0.00
Sole dispositive power
1088114.27
Shared dispositive power
0.00
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of BIO-TECHNE CORP. No one other person's interest in the COMMON STOCK of BIO-TECHNE CORP is more than five percent of the total outstanding COMMON STOCK.
Item 7
Not applicable indication
N
Subsidiaries
See attached Exhibit 99.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Please see Exhibit 99 for 13d-1(k) (1) agreement.
Signature comments
* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Signature 1
- Reporting person
- FMR LLC
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
- Date
- 11/04/2026
Signature 2
- Reporting person
- Abigail P. Johnson
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
- Date
- 11/04/2026
Filed exhibits
- EX-99 ↗exhibit99.txt
Company context
Bio Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer focused brands: R&D Systems™, Bio Techne Spatial™, and Bio Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision making. Bio Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.